PI3K Inhibition for Squamous Cell Head and Neck Carcinoma

被引：5
|
作者：
Desilets, Antoine [1 ,2 ]
Soulieres, Denis [1 ]
机构：
[1] Ctr Hosp Univ Montreal CHUM, Pavillon C,1000 Rue St Denis, Montreal, PQ H2X 0C1, Canada
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER JOURNAL | 2022年 / 28卷 / 05期
关键词：
Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy; PHOSPHOINOSITIDE 3-KINASE INHIBITOR; I DOSE-ESCALATION; BUPARLISIB BKM120; PACLITAXEL; RECURRENT; CHEMOTHERAPY; COMBINATION; EXPRESSION; RECEPTOR; NIVOLUMAB;
D O I：
10.1097/PPO.0000000000000618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
引用
收藏
页码：369 / 376
页数：8
相关论文
共 50 条
  • [31] Integrative drug sensitivity analysis of PI3K/mTOR pathway inhibitors in Head and Neck Squamous Cell Carcinoma (HNSCC)
    Sambandam, Vaishnavi
    Shen, Li
    Zhang, Ming
    Saigal, Rishi
    Byers, Lauren A.
    Pickering, Curtis
    Myers, Jeffrey N.
    Wang, Jing
    Johnson, Faye M.
    CANCER RESEARCH, 2015, 75
  • [32] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, A.
    DeGraff, W.
    Choudhuri, R.
    Sowers, A. L.
    Thetford, A.
    Cook, J. A.
    Van Waes, C.
    Mitchell, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S196 - S197
  • [33] A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
    Mazumdar, Tuhina
    Byers, Lauren A.
    Ng, Patrick Kwok Shing
    Mills, Gordon B.
    Peng, Shaohua
    Diao, Lixia
    Fan, You-Hong
    Stemke-Hale, Katherine
    Heymach, John V.
    Myers, Jeffrey N.
    Glisson, Bonnie S.
    Johnson, Faye M.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (11) : 2738 - 2750
  • [34] Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma
    Burrows, F.
    Shivani, M.
    Wang, Z.
    Chan, S.
    Gilardi, M.
    Gutkind, S.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S43 - S44
  • [35] HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
    Elisabeth Foki
    Isabella Stanisz
    Lorenz Kadletz
    Ulana Kotowski
    Rudolf Seemann
    Rainer Schmid
    Gregor Heiduschka
    Wiener klinische Wochenschrift, 2021, 133 : 26 - 31
  • [36] HS-173, a selective PI3K inhibitor, induces cell death in head and neck squamous cell carcinoma cell lines
    Foki, Elisabeth
    Stanisz, Isabella
    Kadletz, Lorenz
    Kotowski, Ulana
    Seemann, Rudolf
    Schmid, Rainer
    Heiduschka, Gregor
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (1-2) : 26 - 31
  • [37] Identification of NOTCH1 inactivating mutation as a therapeutic vulnerability to PI3K/mTOR pathway inhibition in head and neck squamous cell carcinoma (HNSCC)
    Sambandam, Vaishnavi
    Shen, Li
    Tong, Pan
    Mazumdar, Tuhina
    Pickering, Curtis
    Myers, Jeffrey N.
    Wang, Jing
    Frederick, Mitchell
    Johnson, Faye M.
    CANCER RESEARCH, 2017, 77
  • [38] HRAS G12V predicts for innate resistance to PI3Kα inhibition in head and neck squamous cell cancer
    Ruicci, Kara M.
    Sun, Ren
    Black, Morgan
    Pinto, Nicole
    Yoo, John
    Fung, Kevin
    Macneil, Danielle
    Aillies, Lauire
    Mymryk, Joseph S.
    Boutros, Paul C.
    Barrett, John W.
    Nichols, Anthony C.
    CANCER RESEARCH, 2017, 77
  • [39] Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway
    Yang, Jing
    Zhu, Xin-jiang
    Jin, Ming-zhu
    Cao, Zhi-wei
    Ren, Yao-yao
    Gu, Zhao-wei
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 316
  • [40] PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma
    Wang, Libo
    Chen, Kejun
    Weng, Siyuan
    Xu, Hui
    Ren, Yuqing
    Cheng, Quan
    Luo, Peng
    Zhang, Jian
    Liu, Zaoqu
    Han, Xinwei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
12345